Table 3.
Impact of precise co-morbidities on 28-day mortality
| Co-morbidity | Odds ratio | 95% confidence intervals | p-value |
|---|---|---|---|
| Patients with acute pyelonephritis | |||
| Chronic heart failure | 2.54 | 1.82–3.55 | < 0.0001 |
| Chronic renal disease | 1.71 | 1.13–2.60 | 0.011 |
| Non-metastatic solid tumor malignancy | 2.13 | 1.44–3.17 | < 0.0001 |
| Corticosteroid intake | 2.05 | 1.09–3.84 | 0.024 |
| Stroke | 2.97 | 2.12–4.17 | < 0.0001 |
| Dementia | 2.18 | 1.51–3.15 | < 0.0001 |
| Patients with community-acquired pneumonia | |||
| Coronary heart disease | 1.87 | 1.30–2.69 | 0.001 |
| Dementia | 2.20 | 1.53–3.17 | < 0.0001 |
| Patients with intraabdominal infections | |||
| Type 2 diabetes mellitus | 1.84 | 1.16–2.93 | 0.010 |
| Chronic renal disease | 2.67 | 1.12–6.35 | 0.026 |
| Non-metastatic solid tumor malignancy | 3.03 | 1.79–5.13 | < 0.0001 |
| Atrial fibrillation | 2.23 | 1.11–4.48 | 0.024 |
| Dementia | 3.69 | 1.87–7.25 | < 0.0001 |
| Liver cirrhosis | 4.59 | 1.20–17.51 | 0.025 |
| Patients with primary bacteremia | |||
| Dementia | 3.87 | 1.65–9.12 | 0.002 |
Only variables remaining significant after the final step of logistic forward conditional regression analysis are included